How Much Does Metoprolol Lower Heart Rate by Dose?

Metoprolol lowers resting heart rate in a dose-dependent pattern, but the relationship is not a straight line. At low oral doses, each added milligram produces a relatively large drop in heart rate, while at higher doses the effect flattens out toward a ceiling of roughly 25 to 30 percent maximum reduction in exercise-induced heart rate. In practice, the size of the drop you experience depends not just on the dose but on your genetics, your sex, the formulation you take, and what your heart rate is responding to in the first place.

The Dose-Response Curve Is Steeper Than You Think at Low Doses

One of the clearest demonstrations of how metoprolol’s heart-rate-lowering effect scales with dose comes from a pharmacogenomics study that tested three escalating oral doses. In that trial, resting heart rate fell by about 4 to 6 percent at the lowest dose, about 6 to 10 percent at the middle dose, and about 11 to 14 percent at the highest dose, depending on the genetic group being studied.¹ The pattern held for both resting and exercise heart rates. So if your resting pulse is 80 beats per minute, a moderate oral dose might bring it down somewhere into the low 70s, while a higher dose could push it into the mid-to-upper 60s.

But there is a built-in ceiling. Researchers who pooled data from conventional and controlled-release metoprolol at 200 mg found that the maximum possible reduction in exercise heart rate (expressed as beta-1 blockade) tops out around 28 percent.² That means once you reach the plasma concentration that produces about half of the maximum effect, you need a disproportionately large dose increase to squeeze out a little more heart rate reduction. Going from 50 mg to 100 mg might noticeably slow your pulse. Going from 200 mg to 400 mg probably will not add much.

What the Heart Failure Trials Reveal About Low Versus High Doses

Heart failure is one of the best-studied settings for metoprolol dosing, and the data from the large MERIT-HF trial offers a useful insight. Patients on lower doses of metoprolol CR/XL (under 100 mg daily) and those on higher doses (100 mg or more) ended up at roughly the same resting heart rate of about 67 beats per minute after three months of treatment. The lower-dose group achieved a mean drop of about 14 beats per minute, while the higher-dose group dropped about 16 beats per minute from baseline.³ That similarity is striking. It means the lower-dose patients were more sensitive per milligram: they got about 0.21 beats per minute of reduction for each milligram of metoprolol, compared to 0.08 beats per minute per milligram in the higher-dose group.

Both dose groups saw the same relative reduction in mortality, about 38 percent compared to placebo.³ That finding has fueled an ongoing debate about whether the target in heart failure should be the highest tolerated dose or the heart rate itself. Analysis of the broader data suggests that a greater reduction in heart rate is associated with better outcomes overall, and that higher doses can help patients whose heart rate stays elevated.⁴ In heart failure, treatment typically starts very low, around 12.5 to 25 mg daily, and is increased every two weeks toward a target of 200 mg daily or whatever the patient can tolerate.⁵

Exercise Heart Rate Drops More Than Resting Heart Rate

If you look only at resting numbers, metoprolol’s effect can seem modest, maybe 5 to 15 beats per minute depending on the dose. But during exercise the drug’s impact becomes much more apparent, because exercise triggers a surge of adrenaline that metoprolol directly opposes. In patients with heart conditions like hypertrophic cardiomyopathy, metoprolol significantly lowered peak exercise heart rate compared to placebo and also reduced the pressure gradient across the heart’s outflow tract during exertion.⁶

A comparison with carvedilol in heart failure patients illustrates metoprolol’s stronger grip on exercise heart rate. Patients on a mean daily dose of about 96 mg of metoprolol succinate had a peak exercise heart rate of around 117 beats per minute, compared to 135 beats per minute in patients on carvedilol, even though both groups started at similar resting heart rates in the low 70s.⁷ That gap matters for people who notice their heart rate climbing during activity and want to know whether the drug will keep it in check.

Mental stress counts too. In studies of psychological stress, metoprolol cut the heart rate response roughly in half compared to what would happen without the drug.⁸ So when people take metoprolol for performance anxiety or situational stress, the effect is real and measurable, though blood pressure responses to stress tend to persist.

Tartrate Versus Succinate and How Formulation Matters

Metoprolol comes in two main formulations: metoprolol tartrate (immediate-release, taken twice daily) and metoprolol succinate (extended-release, taken once daily). The most common clinical question is whether one slows the heart more than the other. In a head-to-head comparison in patients with heart failure, both formulations produced equivalent hemodynamic and functional benefits, with no meaningful difference in heart rate reduction between the two.⁹

The pharmacokinetic study that established the ceiling effect also compared the two formulations and found that the absorption rate did not alter the concentration-effect relationship.² In other words, what matters is the total amount of drug reaching your bloodstream over the dosing interval, not how quickly it peaks. The extended-release version smooths out the plasma level so you avoid the troughs that come with twice-daily dosing, which can translate into more consistent heart rate control throughout the day and night. But the total heart rate reduction at equivalent daily doses is similar.

Your Genetics Can Shift the Response by Several Beats Per Minute

Metoprolol is broken down in the liver primarily by an enzyme called CYP2D6, and genes for that enzyme vary considerably across the population. People who metabolize drugs slowly through this pathway (poor metabolizers) end up with higher blood levels of metoprolol at the same dose, and their hearts feel it. A meta-analysis of 15 studies covering over a thousand individuals found that poor metabolizers had an additional 3 beats per minute of heart rate reduction compared to normal metabolizers taking similar doses.¹⁰

That might sound small, but it stacks with other factors. A separate study found that people with two copies of the slowest-metabolizing gene variant had a resting heart rate about 8.5 beats per minute lower than fast metabolizers, and their risk of developing an abnormally slow heart rate (bradycardia) was almost four times higher.¹¹ In a clinical study that examined this directly, CYP2D6 status was among the strongest predictors of how much a patient’s heart rate dropped on metoprolol, alongside age, baseline heart rate, and race.¹²

There is also a separate genetic layer involving the receptor that metoprolol targets. People who carry two copies of the Arg389 variant of the beta-1 adrenergic receptor showed greater heart rate reduction at every dose level compared to those carrying the Gly389 variant, with the gap widening at higher doses.¹ So two people on the same dose can have meaningfully different results depending on both how fast they clear the drug and how responsive their receptors are.

Women Appear More Sensitive to Heart Rate Lowering

Sex-based differences in metoprolol response have been documented in several studies. In healthy volunteers, women experienced a greater reduction in exercise heart rate than men after the same dose.¹³ One reason is pharmacokinetic: women tend to have higher plasma levels of metoprolol for the same oral dose, partly because of differences in body composition and metabolism.

A population-based study made the clinical implication clearer. In women, higher metoprolol plasma levels were significantly correlated with lower heart rate, while in men no such correlation reached significance.¹⁴ Women with the highest plasma levels had a dramatically higher risk of bradycardia compared to those with the lowest levels. In men, the risk did not significantly differ between high and low plasma level groups.¹⁴ Pharmacokinetic modeling has suggested that at a plasma concentration of roughly 25 to 28 ng/mL, you can expect about a 10 percent reduction in systolic blood pressure and more than a 15 percent reduction in heart rate from baseline, though the steepness of the dose-response curve differs between men and women.¹⁵

Intravenous Metoprolol for Rapid Atrial Fibrillation

When someone shows up to an emergency department with atrial fibrillation and a racing heart, intravenous metoprolol is a common first-line option. The weight-based dose studied in trials is typically around 0.15 mg per kilogram of body weight, capped at about 10 mg. In one randomized trial comparing this to IV diltiazem, metoprolol was slower to act: only 15 percent of patients reached treatment success at 2 minutes versus 50 percent for diltiazem, though the gap closed by 5 to 20 minutes.¹⁶ Treatment success in these trials was defined as either getting the heart rate below 100 beats per minute, achieving a 20 percent reduction from the starting rate, or converting to a normal rhythm.

One clinically useful detail: patients who had never been on a beta-blocker before were significantly more likely to respond to IV metoprolol than patients already taking one chronically. In a study of nearly 400 patients, about 56 percent of beta-blocker-naive patients achieved rate control compared to about 42 percent of those on chronic therapy.¹⁷ That makes intuitive sense: someone already on a beta-blocker has less room for additional receptor blockade, and their atrial fibrillation has already “broken through” whatever protection the drug was providing.

When Bradycardia Becomes the Problem

The same property that makes metoprolol useful, slowing the heart, can become a safety issue when the heart slows too much. In the GENETIC-AF trial, more than half of patients randomized to metoprolol developed at least one episode of heart rate below 60 beats per minute during six months of follow-up, and about 22 percent dropped below 50 beats per minute.¹⁸ During episodes of severe bradycardia, mean heart rates dipped to about 44 to 45 beats per minute. These events were far more common with metoprolol than with bucindolol, a genetically targeted beta-blocker used as the comparator.

The risk of bradycardia is amplified by several of the factors already mentioned: being a CYP2D6 poor metabolizer, being female, being elderly, or taking other drugs that slow the heart such as calcium channel blockers or digoxin. The relationship between dose and bradycardia is not simply linear either. Because metoprolol’s heart-rate-lowering effect plateaus at higher doses, the risk of excessive slowing rises more steeply when someone who is already near the ceiling gets an additional push from a drug interaction or a genetic variant they do not know about.

Why Metoprolol Loses Its Selectivity at Higher Doses

At low doses, metoprolol preferentially blocks beta-1 receptors, which are the ones in the heart. This is why it is called a “cardioselective” beta-blocker. But that selectivity is dose-dependent. In a study comparing metoprolol succinate and carvedilol in heart failure patients, metoprolol maintained its beta-1 selectivity at low doses but became progressively less selective at higher doses.¹⁹ At high doses, it starts blocking beta-2 receptors as well, which are found in the lungs and blood vessels. For most people this does not matter much, but for anyone with asthma or reactive airway disease, higher doses of metoprolol carry a greater risk of triggering bronchospasm. The practical takeaway is that metoprolol is not infinitely “safe for the lungs” just because it is labeled cardioselective; that label describes its behavior at low-to-moderate doses.

Beta-blockers that lack intrinsic sympathomimetic activity, like metoprolol and timolol, also lower resting heart rate more than those that have it, like pindolol and oxprenolol.²⁰ This distinction matters when a clinician is choosing between beta-blockers for someone who already has a low resting heart rate but needs rate control during exercise or stress.

What Happens When You Stop

If you have been on metoprolol for a while and stop abruptly, your heart rate does not simply return to where it was before. It overshoots. In a study of patients withdrawn from chronic metoprolol therapy, resting heart rate rebounded by about 15 percent above on-treatment values within two to eight days.²¹ At the same time, the heart’s sensitivity to adrenaline-like stimulation surged by about 52 percent. This rebound is not just a lab curiosity. In patients with ischemic heart disease, gradual withdrawal of metoprolol still produced a rebound increase in both resting heart rate and heart rate responses to standing, along with unmasking of angina symptoms.²²

The mechanism is receptor upregulation: when you chronically block beta receptors, your body grows more of them or makes the existing ones more sensitive. Remove the blockade suddenly and all those extra receptors are now available for adrenaline to act on, producing an exaggerated response. This is why standard practice is to taper metoprolol gradually over one to two weeks rather than stopping all at once, especially in anyone with coronary artery disease.

Drug Interactions That Amplify the Heart Rate Drop

Metoprolol’s heart rate effect can stack with that of other medications that slow conduction through the heart. The combination of metoprolol and the calcium channel blocker verapamil, for example, has been studied in patients with angina. When verapamil was given alone, it lowered blood pressure without much heart rate change. Metoprolol alone lowered heart rate without changing blood pressure. Together, both blood pressure and heart rate dropped, and the heart rate effect was more pronounced than with either drug alone.²³ This particular combination requires careful monitoring because both drugs slow the heart through overlapping but distinct mechanisms, and together they can push someone into symptomatic bradycardia or heart block.

CYP2D6 inhibitors add another layer. Common medications like fluoxetine, paroxetine, and bupropion partially block the enzyme that metabolizes metoprolol, which can raise metoprolol plasma levels and intensify the heart rate reduction even without changing the dose. For anyone on one of these medications, the effective dose of metoprolol is higher than the number on the pill bottle suggests. This is another reason the same written dose can produce very different heart rate results from person to person.